ClinicalTrials.gg
CompletedNCT01508923Updated Jan 24, 2017

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

A Phase 2 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-24.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
131st of 151
17 · median 62
Started
2001
with 4 others
Phase 2
18 of 151
2 open now
Registered
41st of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 131st largest by enrollment, is one of 5 that started in 2001, is one of 18 in phase 2, and was the 41st registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 17 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included
  • (BMI) maximum 35 kg/m\^2
  • Fasting plasma glucose 7-15 mmol/l, both inclusive

Exclusion criteria

Exclusion Criteria:

  • Impaired liver function
  • Impaired renal function
  • Anaemia
  • Cardiac disease
  • Uncontrolled treated/untreated hypertension
  • Recurrent major hypoglycaemia as judged by the Investigator
  • Known or suspected allergy to trial product or related products
  • Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate measures
  • Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
  • Loss of more than 400 ml blood during the three months prior to study start
  • Allergy to paracetamol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment period 1

    Drug: liraglutide · Drug: placebo

  • Placebo comparator
    Treatment period 2

    Drug: liraglutide · Drug: placebo

Interventions

  • 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

    Also known as: NNC 90-1170

  • Drugplacebo

    6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

07

What researchers measure

Primary outcomes

  1. 24-hour glucose profiles after three fixed meals

Secondary outcomes

  1. 24-hour insulin profiles after three fixed meals

  2. First phase insulin and maximal insulin secretory capacity

  3. EGR (endogenous glucose release) expressed in mg/kg/min

  4. GNG (gluconeogenesis) expressed in mg/kg/min

  5. 24-hour glucagon profiles after three fixed meals

  6. 24-hour FFA (free fatty acids) profiles after three fixed meals

  7. 4-hour paracetamol profiles after two fixed meals

  8. 30-hour NNC 90-1170 profile

  9. Adverse events

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
09

References and documents

Publications

  • Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187. PubMed 15111485 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2001, a primary completion of Feb 2002 and a completion of Feb 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2012
First posted
Jan 12, 2012
Start
May 2001
Primary completionActual
Feb 2002
CompletionActual
Feb 2002
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01508923
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 12, 2012
Start date
May 2001
Primary completion
Feb 2002
Completion
Feb 2002
Last update
Jan 24, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion